My hypothesis and questions about ALS became timely again in September 2026 when Novartis confirmed that it would discontinue development of lifonebart, also known as VHB937, for ALS after the Phase 2 ASTRALS trial failed to meet its primary and secondary endpoints. I explain details based on personal and professional research.
But instead, Mr. Thompson (name changed) handed my project to Jake, who didn’t deserve it. Plus, he always gossiped about him. At Diwali dinner, my heart was still heavy. My grandpa saw my long face…
Someone, either because they love music or because they secretly wanted to torture parents, recently gave my young son a xylophone. In a vague hope to encourage an interest in music, I’ll tap out the…
AI Adoption & The Age Of Crisis Are you really being “left behind?” AI adoption is one of those topics that actually force my brain to leave my body, and honestly, I’m not sure I’m going to …
Linux Can Be Incredibly Frustrating But it’s worth the fight When I switched to Linux at the end of 2025, I knew that it wouldn’t be all sunshine and roses. I knew that there would be roadblocks …
Ubuntu Hate is So Overblown. It’s Still a Great Distro.
Beyond Meat 2026 Q2 Earnings Explained
Who’s Afraid of Their TBR?
Fedora KDE Edition is Fantastic, But Should You Switch?
Beyond Meat’s Beyond Steak Filet Expands to Meijer: A Small but Important Turnaround Signal
Your Camera, Your Pictures, Your AI
Microsoft’s September Updates for Windows 11 Broke Things. Again.
I Sold Micron Too Early. Here’s the Investing Lesson I’m Taking From It.
The Seedless Conspiracy That Has Me Shook
Linux Can Be Incredibly Frustrating
Beyond Steak Filet Hits Stores After Record Sales
Help! Was my Wife Was Kidnapped by Aliens
My Multi-Monitor Setup Was KILLING My Productivity
Be featured on our homepage daily.
Placeholder description lin 1
Placeholder description line 2
Placeholder description line 3
The top writers this week. View all
